Search

Displaying results 171 - 180 of 9774 in total
  1. Drug

    Viagenpumatucel-L

    go.drugbank.com/drugs/DB16348
    Investigational

    Viagenpumatucel-L is under investigation in clinical trial NCT02117024 (A Phase 2 Study of Viagenpumatucel-l (HS-110) in Patients With Non-small Cell Lung Cancer).

    Synonyms: Gp96-igg1-fc fusion protein and hla-a1 expressing, irradiated ad-100 whole cell vaccine
  2. Drug

    Nendratareotide uzatansine

    go.drugbank.com/drugs/DB18351
    Investigational

    Nendratareotide uzatansine is a peptide-drug conjugate comprising a peptide analog of somatostatin conjugated to the cytotoxin mertansine.

    Synonyms: Peptide-drug conjugate combining [(Tyr3,Cys8) octreotate amide] and N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl) maytansine
  3. Drug

    TRK-001

    go.drugbank.com/drugs/DB18577
    Investigational

    TRK-001 is an autologous regulatory T-cell therapy. It is being investigated for the prevention of graft rejection following solid organ transplantation.

    Synonyms: Natural Regulatory T Cells (T-Regs), Expanded with Interleukin-2, ExpAct Beads (CD3/CD28; Miltenyi), Rapamycin and Transforming Growth Factor-beta
  4. Drug

    CLL1-CD33 compound chimeric antigen receptor T cells

    go.drugbank.com/drugs/DB18568
    Investigational

    Synonyms: Chimeric Antigen Receptor immunotherapy directed against CLL-1 and CD33
  5. Drug

    Telcagepant

    go.drugbank.com/drugs/DB12228
    Investigational

    CGRP and its receptors are found in areas of the central and peripheral nervous system that are important for the transmission of migraine pain. … During migraine attacks, CGRP activates these receptors and facilitates the transmission of pain impulses.

    Salts: Telcagepant potassium
  6. Drug

    Fepixnebart

    go.drugbank.com/drugs/DB19079
    Investigational

    Fepixnebart is under investigation in clinical trial NCT04456686 (Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Osteoarthritis).

    Synonyms: Ly3016859 (humanized monoclonal antibody to human tgf.alpha. and epiregulin), IMMUNOGLOBULIN G4 (226-PROLINE,232-ALANINE,233-ALANINE,DE-C-TERMINAL-LYSINE), ANTI-(HUMAN EPIREGULIN AND TRANSFORMING GROWTH FACTOR .ALPHA.)
  7. Drug

    Sucrosofate

    go.drugbank.com/drugs/DB01901
    Investigational

    Salts: Sucrosofate potassium
  8. Drug

    Acesulfame

    go.drugbank.com/drugs/DB16868
    Investigational

    Salts: Acesulfame potassium
  9. Drug

    DT-DEC01

    go.drugbank.com/drugs/DB19433
    Experimental

    DT-DEC01 is a novel Dystrophin Expressing Chimeric (DEC) cell therapy being investigated by Dystrogen Therapeutics Corporation.

    Synonyms: Dystrophin Expressing Chimeric Cells derived from allogenic normal human myoblast and autologous DMD myoblast from Duchenne muscular dystrophy affected donor
  10. Drug

    Incadronic acid

    go.drugbank.com/drugs/DB06255
    Experimental

    Along with being investigated to treat hypercalcemia of malignancy,[A202862] it has also been investigated in the treatment of myeloma, leukemia, and other cancers.

    Salts: Disodium incadronate